Programmed cell death ligand-1(PD-L1)is a T cell inhibitory immune checkpoint molecule that interacts with programmed cell death-1(PD-1)to promote immune escape of tumor cells.Compared with antibody therapies,small mo...Programmed cell death ligand-1(PD-L1)is a T cell inhibitory immune checkpoint molecule that interacts with programmed cell death-1(PD-1)to promote immune escape of tumor cells.Compared with antibody therapies,small molecule drugs show better prospects due to their advantages such as higher bioavailability,better tissue penetration,and reduced risk of immunogenicity.Here,we found that the small molecule demethylzeylasteral(Dem)can significantly downregulate the expression of PD-L1 in colorectal cancer cells and enhance the killing effect of T cells on tumor cells.Mechanistically,Dem binds to the deubiquitinating enzyme USP22 and promotes its degradation,resulting in increased ubiquitination and degradation of PD-L1 through the proteasome pathway.In addition,Dem increased the activity of cytotoxic T cells and reduced the number of myeloid-derived suppressor cells(MDSCs)and regulatory T cells(Tregs)in tumor-infiltrating lymphocytes(TILs),thereby activating the tumor immune microenvironment and inhibiting the growth of subcutaneous MC38 tumors in C57BL/6 mice.Moreover,we also found that the combination of Dem and CTLA4 antibodies can further improve the efficacy of antitumor therapy.Our study reveals the mechanism by which Dem promotes PD-L1 degradation and suggests that the combination of Dem and CTLA4 antibodies may improve the efficacy of immunotherapy.展开更多
To the Editor:ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport1. The dysregulation of ARF1 expression and/or activity is involved in many human cancers, such as brea...To the Editor:ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport1. The dysregulation of ARF1 expression and/or activity is involved in many human cancers, such as breast cancer2,3. Therefore, ARF1 is one of the promising therapeutic targets for cancer treatment.展开更多
基金funded by the National Key Research and Development Program of China(2022YFC3502000)National Natural Science Foundation of China(Nos.82141203,82374086,and 82104459)+3 种基金Shanghai Municipal Science and Technology Major Project(ZD2021CY001,China)Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTDD-202004,China)Science and Technology Commission of Shanghai Municipality(20YF1458700,China)Organizational Key Research and Development Program of Shanghai University of Traditional Chinese Medicine(2023YZZ02,China)。
文摘Programmed cell death ligand-1(PD-L1)is a T cell inhibitory immune checkpoint molecule that interacts with programmed cell death-1(PD-1)to promote immune escape of tumor cells.Compared with antibody therapies,small molecule drugs show better prospects due to their advantages such as higher bioavailability,better tissue penetration,and reduced risk of immunogenicity.Here,we found that the small molecule demethylzeylasteral(Dem)can significantly downregulate the expression of PD-L1 in colorectal cancer cells and enhance the killing effect of T cells on tumor cells.Mechanistically,Dem binds to the deubiquitinating enzyme USP22 and promotes its degradation,resulting in increased ubiquitination and degradation of PD-L1 through the proteasome pathway.In addition,Dem increased the activity of cytotoxic T cells and reduced the number of myeloid-derived suppressor cells(MDSCs)and regulatory T cells(Tregs)in tumor-infiltrating lymphocytes(TILs),thereby activating the tumor immune microenvironment and inhibiting the growth of subcutaneous MC38 tumors in C57BL/6 mice.Moreover,we also found that the combination of Dem and CTLA4 antibodies can further improve the efficacy of antitumor therapy.Our study reveals the mechanism by which Dem promotes PD-L1 degradation and suggests that the combination of Dem and CTLA4 antibodies may improve the efficacy of immunotherapy.
基金supported by the National Natural Science Foundation of China (81903639 to Sulin Zhang,China)Lingang Laboratory (LG202102-01-02 to Mingyue Zheng,China,LG-QS-202204-01 to Sulin Zhang,China)+1 种基金Shanghai Municipal Science and Technology Major Project (Hualiang Jiang,China)Shanghai Sailing Program (19YF1457800 to Sulin Zhang,China)。
文摘To the Editor:ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport1. The dysregulation of ARF1 expression and/or activity is involved in many human cancers, such as breast cancer2,3. Therefore, ARF1 is one of the promising therapeutic targets for cancer treatment.
